매독 면역 측정 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Syphilis Immunoassay Diagnostics Market - Scope of Report

TMR's report on the global syphilis immunoassay diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global syphilis immunoassay diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global syphilis immunoassay diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the syphilis immunoassay diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global syphilis immunoassay diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global syphilis immunoassay diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global syphilis immunoassay diagnostics market.

The report delves into the competitive landscape of the global syphilis immunoassay diagnostics market. Key players operating in the global syphilis immunoassay diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global syphilis immunoassay diagnostics market profiled in this report.

Key Questions Answered in Global syphilis immunoassay diagnostics Market Report:

• What is the sales/revenue generated by syphilis immunoassay diagnostics across all regions during the forecast period?
• What are the opportunities in the global syphilis immunoassay diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Syphilis Immunoassay Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global syphilis immunoassay diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global syphilis immunoassay diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global syphilis immunoassay diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Syphilis Immunoassay Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.4.2. Market Volume/Unit Shipments Projections
• 4.5. Porter's Five Force Analysis

5. Key Insights

• 5.1. Key Industry Events
• 5.2. Distributors Landscape
• 5.3. PORTER's Five Forces Analysis
• 5.4. End-user Preference
• 5.5. Epidemiology of Syphilis by Region/Countries
• 5.6. Government Initiatives by Region/Countries
• 5.7. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
• 5.8. PESTEL Analysis
• 5.9. Impact of near patient testing and POC on syphilis market dynamics
• 5.10. Brand and Pricing Analysis
• 5.11. Regulatory Scenario by Region/ Country
• 5.12. Supply Chain Analysis
• 5.13. Technological Advancements

6. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Product

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Product, 2020-2034
  • 6.3.1. Analyzer
  • 6.3.2. Kits & Reagents
• 6.4. Market Attractiveness By Product

7. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Technology

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Technology, 2020-2034
  • 7.3.1. Chemiluminescence Assay (CLIA)
  • 7.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 7.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 7.3.4. Treponema pallidum latex agglutination (TPLA)
  • 7.3.5. Non-treponemal Flocculation Assay
• 7.4. Market Attractiveness By Technology

8. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Test Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Test Type, 2020-2034
  • 8.3.1. Treponemal Tests
  • 8.3.2. Non-Treponemal Tests
• 8.4. Market Attractiveness By Test Type

9. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Location of Testing

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Location of Testing, 2020-2034
  • 9.3.1. Point-of-care testing (POCT)
  • 9.3.2. Patient Self-Tests (PST)
  • 9.3.3. Clinical Settings
• 9.4. Market Attractiveness By Location of Testing

10. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By End-user, 2020-2034
  • 10.3.1. Hospitals and Clinics
  • 10.3.2. Diagnostics Laboratories
  • 10.3.3. Home Care
  • 10.3.4. Public Health Laboratory
  • 10.3.5. Others
• 10.4. Market Attractiveness By End-user

11. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Region

• 11.1. Key Findings
• 11.2. Market Value Forecast By Region
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness By Country/Region

12. North America Syphilis Immunoassay Diagnostics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Product, 2020-2034
  • 12.2.1. Analyzer
  • 12.2.2. Kits & Reagents
• 12.3. Market Value Forecast By Technology, 2020-2034
  • 12.3.1. Chemiluminescence Assay (CLIA)
  • 12.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 12.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 12.3.4. Treponema pallidum latex agglutination (TPLA)
  • 12.3.5. Non-treponemal Flocculation Assay
• 12.4. Market Value Forecast By Test Type, 2020-2034
  • 12.4.1. Treponemal Tests
  • 12.4.2. Non-Treponemal Tests
• 12.5. Market Value Forecast By Location of Testing, 2020-2034
  • 12.5.1. Point-of-care testing (POCT)
  • 12.5.2. Patient Self-Tests (PST)
  • 12.5.3. Clinical Settings
• 12.6. Market Value Forecast By End-user, 2020-2034
  • 12.6.1. Hospitals and Clinics
  • 12.6.2. Diagnostics Laboratories
  • 12.6.3. Home Care
  • 12.6.4. Public Health Laboratory
  • 12.6.5. Others
• 12.7. Market Value Forecast By Country, 2020-2034
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Product
  • 12.8.2. By Technology
  • 12.8.3. By Test Type
  • 12.8.4. By Location of Testing
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Syphilis Immunoassay Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Product, 2020-2034
  • 13.2.1. Analyzer
  • 13.2.2. Kits & Reagents
• 13.3. Market Value Forecast By Technology, 2020-2034
  • 13.3.1. Chemiluminescence Assay (CLIA)
  • 13.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 13.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 13.3.4. Treponema pallidum latex agglutination (TPLA)
  • 13.3.5. Non-treponemal Flocculation Assay
• 13.4. Market Value Forecast By Test Type, 2020-2034
  • 13.4.1. Treponemal Tests
  • 13.4.2. Non-Treponemal Tests
• 13.5. Market Value Forecast By Location of Testing, 2020-2034
  • 13.5.1. Point-of-care testing (POCT)
  • 13.5.2. Patient Self-Tests (PST)
  • 13.5.3. Clinical Settings
• 13.6. Market Value Forecast By End-user, 2020-2034
  • 13.6.1. Hospitals and Clinics
  • 13.6.2. Diagnostics Laboratories
  • 13.6.3. Home Care
  • 13.6.4. Public Health Laboratory
  • 13.6.5. Others
• 13.7. Market Value Forecast By Country, 2020-2034
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Product
  • 13.8.2. By Technology
  • 13.8.3. By Test Type
  • 13.8.4. By Location of Testing
  • 13.8.5. By End-user
  • 13.8.6. By Country

14. Asia Pacific Syphilis Immunoassay Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Product, 2020-2034
  • 14.2.1. Analyzer
  • 14.2.2. Kits & Reagents
• 14.3. Market Value Forecast By Technology, 2020-2034
  • 14.3.1. Chemiluminescence Assay (CLIA)
  • 14.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 14.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 14.3.4. Treponema pallidum latex agglutination (TPLA)
  • 14.3.5. Non-treponemal Flocculation Assay
• 14.4. Market Value Forecast By Test Type, 2020-2034
  • 14.4.1. Treponemal Tests
  • 14.4.2. Non-Treponemal Tests
• 14.5. Market Value Forecast By Location of Testing, 2020-2034
  • 14.5.1. Point-of-care testing (POCT)
  • 14.5.2. Patient Self-Tests (PST)
  • 14.5.3. Clinical Settings
• 14.6. Market Value Forecast By End-user, 2020-2034
  • 14.6.1. Hospitals and Clinics
  • 14.6.2. Diagnostics Laboratories
  • 14.6.3. Home Care
  • 14.6.4. Public Health Laboratory
  • 14.6.5. Others
• 14.7. Market Value Forecast By Country, 2020-2034
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Product
  • 14.8.2. By Technology
  • 14.8.3. By Test Type
  • 14.8.4. By Location of Testing
  • 14.8.5. By End-user
  • 14.8.6. By Country

15. Latin America Syphilis Immunoassay Diagnostics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Product, 2020-2034
  • 15.2.1. Analyzer
  • 15.2.2. Kits & Reagents
• 15.3. Market Value Forecast By Technology, 2020-2034
  • 15.3.1. Chemiluminescence Assay (CLIA)
  • 15.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 15.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 15.3.4. Treponema pallidum latex agglutination (TPLA)
  • 15.3.5. Non-treponemal Flocculation Assay
• 15.4. Market Value Forecast By Test Type, 2020-2034
  • 15.4.1. Treponemal Tests
  • 15.4.2. Non-Treponemal Tests
• 15.5. Market Value Forecast By Location of Testing, 2020-2034
  • 15.5.1. Point-of-care testing (POCT)
  • 15.5.2. Patient Self-Tests (PST)
  • 15.5.3. Clinical Settings
• 15.6. Market Value Forecast By End-user, 2020-2034
  • 15.6.1. Hospitals and Clinics
  • 15.6.2. Diagnostics Laboratories
  • 15.6.3. Home Care
  • 15.6.4. Public Health Laboratory
  • 15.6.5. Others
• 15.7. Market Value Forecast By Country, 2020-2034
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Product
  • 15.8.2. By Technology
  • 15.8.3. By Test Type
  • 15.8.4. By Location of Testing
  • 15.8.5. By End-user
  • 15.8.6. By Country

16. Middle East & Africa Syphilis Immunoassay Diagnostics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Product, 2020-2034
  • 16.2.1. Analyzer
  • 16.2.2. Kits & Reagents
• 16.3. Market Value Forecast By Technology, 2020-2034
  • 16.3.1. Chemiluminescence Assay (CLIA)
  • 16.3.2. Enzyme Linked Immunosorbent Assay (ELISA
  • 16.3.3. Immunochromatographic Assay /Lateral Flow Assay
  • 16.3.4. Treponema pallidum latex agglutination (TPLA)
  • 16.3.5. Non-treponemal Flocculation Assay
• 16.4. Market Value Forecast By Test Type, 2020-2034
  • 16.4.1. Treponemal Tests
  • 16.4.2. Non-Treponemal Tests
• 16.5. Market Value Forecast By Location of Testing, 2020-2034
  • 16.5.1. Point-of-care testing (POCT)
  • 16.5.2. Patient Self-Tests (PST)
  • 16.5.3. Clinical Settings
• 16.6. Market Value Forecast By End-user, 2020-2034
  • 16.6.1. Hospitals and Clinics
  • 16.6.2. Diagnostics Laboratories
  • 16.6.3. Home Care
  • 16.6.4. Public Health Laboratory
  • 16.6.5. Others
• 16.7. Market Value Forecast By Country, 2020-2034
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Product
  • 16.8.2. By Technology
  • 16.8.3. By Test Type
  • 16.8.4. By Location of Testing
  • 16.8.5. By End-user
  • 16.8.6. By Country

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis, by Company (2023)
• 17.3. Company Profiles
  • 17.3.1. Abbott
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. Becton, Dickinson, and Company (BD)
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. bioMerieux SA
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. Bio-Rad Laboratories, Inc
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. Chembio Diagnostics, Inc.
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. Danaher Corporation
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. DiaSorin S.p.A.
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. Roche Diagnostics (F. Hoffmann-La Roche AG)
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Fujirebio
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. QuidelOrtho Corporation
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Shenzhen New Industries Biomedical Engineering Co., Ltd.
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. Siemens Healthineers AG
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. Sekisui Chemical Co Ltd
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments
  • 17.3.14. Thermo Fisher Scientific, Inc.
    • 17.3.14.1. Company Overview
    • 17.3.14.2. Financial Overview
    • 17.3.14.3. Product Portfolio
    • 17.3.14.4. Business Strategies
    • 17.3.14.5. Recent Developments
  • 17.3.15. Trinity Biotech
    • 17.3.15.1. Company Overview
    • 17.3.15.2. Financial Overview
    • 17.3.15.3. Product Portfolio
    • 17.3.15.4. Business Strategies
    • 17.3.15.5. Recent Developments